|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma
|
“My business model when I took over in 2017 was to outsource everything.” That’s as clear as it gets from a biotech CEO. Amit Kumar cuts to the chase during our conversation centered on the newly announced relationship between his company, Anixa Biosciences, and Cytovance Biologics, a U.S.-based CDMO.
|
|
|
|
|
|
|
|
INDUSTRY INSIGHTS CONTINUED
|
|
|
|
|
|
|
|
Direct-To-Patient Supply: Industry Perception And Future Trends
|
|
White Paper | By Samuel Lee, Tatiana Danilova, Shuddhodana Shuddhodana, et al., Catalent
|
To better understand sponsors’ perspectives on DTP distribution of clinical supplies, 234 individuals involved in clinical supply and operations were recently surveyed. Click to get the results!
|
|
|
|
|
|
|
|
|
|
Secondary Packaging: Cartoning And Kitting
|
|
Case Study | Praxis Packaging
|
Fast deployment, scalable production, and rigorous quality control enabled the delivery of over 20 million complex kits in eight months, demonstrating how efficient operations can meet urgent demand.
|
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE
|
|
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.
|
|
|
| Connect With Outsourced Pharma: |
|
|
|
|